Full metadata record

DC FieldValueLanguage
dc.contributor.author김영조ko
dc.contributor.author이민구[이민구]ko
dc.contributor.author정명호[정명호]ko
dc.contributor.author안영근[안영근]ko
dc.contributor.author조정관[조정관]ko
dc.contributor.author박종천[박종천]ko
dc.contributor.author강정채[강정채]ko
dc.contributor.author채성철[채성철]ko
dc.contributor.author허승호[허승호]ko
dc.contributor.author홍택종[홍택종]ko
dc.contributor.author성인환[성인환]ko
dc.contributor.author채제건[채제건]ko
dc.contributor.author류재영[류재영]ko
dc.contributor.author채인호[채인호]ko
dc.contributor.author조명찬[조명찬]ko
dc.contributor.author배장호[배장호]ko
dc.contributor.author라승운[라승운]ko
dc.contributor.author김종진[김종진]ko
dc.contributor.author최동훈[최동훈]ko
dc.contributor.author장양수[장양수]ko
dc.contributor.author윤정한[윤정한]ko
dc.contributor.author정욱성[정욱성]ko
dc.contributor.author승기배[승기배]ko
dc.contributor.author박승정[박승정]ko
dc.date.accessioned2015-12-17T01:14:40Z-
dc.date.available2015-12-17T01:14:40Z-
dc.date.created2015-11-13-
dc.date.issued201109-
dc.identifier.citationCIRCULATION JOURNAL, v.75, no.9, pp.2120 - 2127-
dc.identifier.issn1346-9843-
dc.identifier.urihttp://hdl.handle.net/YU.REPOSITORY/24572-
dc.identifier.urihttp://dx.doi.org/10.1253/circj.CJ-11-0263-
dc.description.abstractBackground: The purpose of the present study was to compare the efficacy and safety of paclitaxel-eluting stent (PES), sirolimus-eluting stent (SES), and zotarolimus-eluting stent (ZES) in primary percutaneous coronary intervention (PCI) for acute ST-segment elevation myocardial infarction (STEMI) with metabolic syndrome (MS). Methods and Results: Using data from Korea Acute Myocardial Infarction Registry (KAMIR; November 2005-December 2007), a total of 1,768 MS patients with STEMI who underwent primary PCI were enrolled: The PES group was 634, SES group, 906, and ZES group, 228. The primary endpoint was major adverse cardiac event (all-cause death, re-myocardial infarction, target lesion revascularization) during 12 months follow-up. At 12 months, the cumulative incidence of primary endpoint in the PES, SES, and ZES groups was 10.9%, 9.1%, and 11.0%, respectively (P=0.086). Incidence of death, recurrent myocardial infarction, or target lesion revascularization did not differ among the 3 groups. There were 7 episodes of acute (0.3% in PES group, 0.4% in SES group, and 0.4% in ZES group, respectively, P=0.773) and 18 episodes of cumulative stent thrombosis including late stent thrombosis (0.9% in PES group, 1.0% in SES group, and 1.3% in ZES group, respectively, P=0.448). Conclusions: Implantation of SES, PES, and ZES in MS patients with STEMI undergoing primary PCI provided comparable clinical outcomes in patients enrolled in KAMIR. (Circ J 2011; 75: 2120-2127)-
dc.language영어-
dc.publisherJAPANESE CIRCULATION SOC-
dc.subjectCORONARY-ARTERY-DISEASE-
dc.subjectBARE-METAL STENTS-
dc.subjectRANDOMIZED-TRIALS-
dc.subjectBALLOON ANGIOPLASTY-
dc.subjectUNCOATED STENTS-
dc.subjectMETAANALYSIS-
dc.subjectRISK-
dc.subjectINTERVENTION-
dc.subjectIMPLANTATION-
dc.subjectEFFICACY-
dc.titleComparison of Paclitaxel-, Sirolimus-, and Zotarolimus-Eluting Stents in Patients With Acute ST-Segment Elevation Myocardial Infarction and Metabolic Syndrome-
dc.typeArticle-
dc.identifier.wosid000294507300018-
dc.identifier.scopusid2-s2.0-80052157400-
Appears in Collections:
의과대학 > 내과학교실 > Articles
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE